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Over the past decade, the availability of targeted bio  logical 
therapies has revolutionized the treatment of rheumatoid 
arthritis, psoriatic arthritis, and ankylosing spondylitis and 
holds promise to expand treatment options for patients 
with systemic lupus erythematosus or other systemic 
autoimmune diseases. However, the signiﬁ   cant cost of 
these medications creates a major barrier that limits 
universal access to these eﬀ   ective thera  peutic agents. 
Whereas generic equivalents are commercially available 
for many small-molecule medica  tions, such lower-cost 
alternatives to targeted biological therapies are not yet 
available in the US or the European Union.
Biopharmaceuticals are medications, predominantly 
proteins, that are manufactured using live organisms. 
Th  ese include blood and plasma products, non-recom-
binant proteins puriﬁ   ed from their natural sources, 
recombinant proteins and monoclonal antibodies pro-
duced in cell culture, vaccines, and cultured cellular and 
tissue products [1]. ‘Follow-on’ protein products are 
those ‘manufactured using biotechnology or derived 
from natural sources that are intended to be suﬃ   ciently 
similar to a’ biopharmaceutical ‘product or products’ 
already approved by a regulatory agency [2]. Th  ese are 
called biosimilars and also have been referred to as 
biogenerics or biocomparables. A biosimilar product is 
deﬁ  ned in Section 351 of the Public Health Service (PHS) 
Act (42 USC § 262) as one which is ‘highly similar to the 
reference product notwithstanding minor diﬀ  erences in 
clinically inactive components’ and for which there are 
‘no clinically meaningful diﬀ   erences between the bio-
logical product and the reference product in terms of 
safety, purity and potency of the product’ [1]. Th  e  term 
‘biogeneric’ is now obsolete because, unlike small-
molecule generic drugs, a biosimilar is never identical to 
its reference product.
A biosimilar etanercept, manufactured in China by CP 
Guojian Pharmaceutical Co., Ltd. (Shanghai), is already 
being marketed in China as Yisaipu [3] and in Colombia 
as Etanar [4]. Several biotechnology companies in Asia 
are also developing biosimilar versions of tumor necrosis 
factor inhibitors. Protalix Biotherapeutics, Inc. (Carmiel, 
Israel) is developing a biosimilar etanercept that is 
expressed in plant cells [5]. Mycenax Biotech (Taiwan) 
has completed early-phase clinical trials of a biosimilar 
etanercept in Southeast Asia: a phase I trial among 24 
healthy subjects in South Korea and a phase I/II trial that 
enrolled 18 patients with rheumatoid arthritis in Taiwan 
[6]. Avesthagen (Bangalore, India) has received a patent 
from the Indian patent oﬃ   ce for a biosimilar etanercept 
[7]. In South Korea, both Celltrion (Yeonsu-gu Incheon 
City) and Aprogen (Daejeon) are developing a biosimilar 
of inﬂ   iximab [8] and LG Life Sciences (Seoul) is 
developing biosimilars of both etanercept and inﬂ  iximab 
to treat rheumatoid arthritis and other inﬂ  ammatory 
diseases [9].
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pies for rheumatic diseases are also being developed. 
Since 2007, Dr. Reddy’s Laboratories Ltd. (Hyderabad, 
India) has marketed Reditux, a biosimilar rituximab, for 
the treatment of non-Hodgkin’s lymphoma and, more 
recently, as Reditux-RA for the treatment of rheumatoid 
arthritis [10]. Two other manufacturers of generic drugs 
are developing biosimilars of rituximab for the treatment 
of rheumatoid arthritis. Teva Pharma  ceutical Industries 
Ltd. (Petach Tikva, Israel) is conduct  ing a phase I/II trial 
comparing the pharmaco  kinetics, pharmacodynamics, 
safety, and preliminary eﬃ   cacy of its biosimilar rituximab 
TL011 with those of MabTh  era® in patients with active 
rheumatoid arthritis (ClinicalTrials.gov identiﬁ  er 
NCT01123070) [11]. Sandoz, the generics division of 
Novartis (Basel, Switzerland), has also initiated a phase II 
clinical trial of its biosimilar rituximab GP2013, assessing 
similar parameters in patients with rheumatoid arthritis 
(ClinicalTrials.gov identiﬁ  er NCT01274182) [12].Biosimilar 
versions of other targeted biological therapies for rheu-
matic diseases have also begun phase I phar  macokinetic 
and pharmaco  dynamic comparative clinical studies [13].
Although no biosimilars have yet been approved for 
treatment of a rheumatic disease, the prospect of their 
impending availability raises several concerns for the 
rheumatologist: (a) Will a biosimilar be as eﬀ  ective as the 
originally licensed biopharmaceutical? (b) Will a bio  similar 
be as safe as the originally licensed biopharma  ceutical? (c) 
If a pharmacist substitutes a biosimilar for a prescribed 
biopharmaceutical, will the patient be adversely aﬀ  ected? 
(d) Will the availability of biosimilars reduce the high cost 
of targeted biological therapies for our patients?
Identical follow-on proteins of certain small peptides, 
for which the amino acid sequences have been deter-
mined, have been synthesized. However, most biosimilars 
are not identical to the original product but exhibit a 
range of structural similarities. Proteins produced by 
recombinant DNA technology are highly similar to the 
original proteins and share the primary amino acid 
sequence but diﬀ   er with respect to glycosylation and 
other post-translational modiﬁ   cations. Other non-
recom  binant proteins that are puriﬁ  ed from their natural 
sources are generally similar to the original biopharma-
ceuticals but, in addition to exhibiting diﬀ  erent  post-
translational modiﬁ   cations, may have slightly diﬀ  erent 
amino acid sequences.
Distinct from biosimilars are ‘second-generation’ bio-
pharmaceuticals that are structurally diﬀ  erent from the 
originally licensed biopharmaceutical and that are 
intended to improve performance while preserving the 
mechanism of action. However, these second-generation 
biopharma  ceuticals are not usually considered to be 
follow-on protein products. Major changes in the 
manufacture of approved protein biopharmaceuticals 
also introduce a degree of uncertainty similar to that 
raised by biosimilars. However, in these situations, the 
original manufacturer maintains access to detailed 
information that pertains to the changes in production 
and that would not be available to the manufacturer of a 
biosimilar.
Manufacturing changes are frequently made by the 
original developers of protein biopharmaceuticals and 
their partners. Some production changes have resulted in 
decreased immunogenicity. When interferon β1a was 
produced by Biogen Idec (Weston, MA, USA) in a new 
cell line, the resulting product, Avonex, had decreased 
immunogenicity compared with the interferon β1a that 
had been produced in the original Chinese hamster ovary 
cell line by Bioferon Biochemische Substanzen GmbH & 
Co. (Laupheim, Germany) [2,14]. On the other hand, 
other changes in formulation or packaging have resulted 
in increased immunogenicity with clinical consequences. 
A change in the formulation of Eprex (recombinant 
human erythro  poietin manufactured by Ortho Biotech, 
part of Janssen, Toronto, ON, Canada), switching the 
protein stabilizer from human serum albumin to the 
detergent polysorbate 80 and introducing a new 
packaging system for sub  cutaneous administration using 
a preﬁ  lled syringe with a rubber plunger, resulted in the 
formation of anti-erythro  poietin antibodies that cross-
reacted with endogenous erythropoietin [15,16]. Th  ese 
cross-reactive antibodies caused 175 patients receiving 
this new formulation of Eprex to develop pure red cell 
aplasia between 1998 and 2004 [17]. Th  us, a change in 
the manufacture of a bio  pharmaceutical may result in an 
outcome that is either beneﬁ  cial or detrimental.
In the US, the process whereby protein and peptide 
drugs, such as enzymes and hormones, are approved and 
licensed by the US Food and Drug Administration (FDA) 
is governed by Section 505 of the Food, Drug, and 
Cosmetic (FD&C) Act (21 US Code [USC] § 355) [18]. In 
contrast, the process by which large, complex bio-
pharmaceuticals, including the targeted biological agents 
used to treat rheumatic diseases, are approved and 
licensed is speciﬁ   ed in Section 351 of the PHS Act 
(42  USC § 262) [1]. Each of these federal statutes 
mandates that the pharmaceutical manufacturer consult 
with the FDA, which acts as the representative of the 
secretary of the US Department of Health and Human 
Services (HHS), prior to commencing the clinical 
develop  ment program to decide upon the ‘design and 
size of clinical trials of a new drug’ that will be necessary 
for the drug to gain approval [18].
Th  e present system of generic drugs in the US was 
established by the Drug Price Competition and Patent 
Term Restoration Act of 1984 (also known as the Hatch-
Waxman Act) (Public Law 98-417). Th  is Act amended 
the FD&C Act and provided two abbreviated pathways 
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source products and recombinant proteins [18]. Section 
505(b)(2) eliminates the unnecessary duplication of 
preclinical and some human studies in the New Drug 
Application (NDA) for a generic drug by allowing direct 
comparison of the generic drug with a product already 
approved for the same indication in brief clinical trials of 
3 to 6 months in duration. Section 505(j) sets forth the 
process by which the producer of a generic drug that is 
identical to a previously approved product can ﬁ  le an 
Abbreviated New Drug Application (ANDA) to seek FDA 
approval of the generic compound. An ANDA allows the 
applicant to rely on the FDA’s previous ﬁ  nding of safety 
and eﬃ   cacy for the already approved drug.
As speciﬁ  ed in Section 505(b)(2) of the FD&C Act, the 
current FDA process for evaluating biosimilar protein 
and peptide drugs in a marketing application allows the 
follow-on applicant to rely, in part, on available know-
ledge about the safety and eﬀ  ectiveness of the structurally 
similar, already approved product. Public access to 
information about the manufacture of the original 
product, such as the source material used and any 
chemical modiﬁ  cations that may have been introduced, 
facilitates this assess  ment. However, this evaluation still 
requires both preclinical and clinical studies to determine 
the safety, purity, and potency of the biosimilar. In this 
way, several natural source products and recombinant 
proteins – for example, natural bovine testicular and 
recombinant human hyaluronidase, recombinant salmon 
calcitonin, recombinant human glucagon, and recom  bi-
nant human somatropin – have been approved as generic 
drugs under Section 505(b)(2) of the FD&C Act. Th  e 
approval of each relied upon structural characterization, 
comparative phar  ma  cokinetic and pharmacodynamic 
data, and immuno  genicity and safety data [2].
Because of the complexity of large biopharmaceuticals, 
the manufacturer of a follow-on protein product has 
diﬃ     culty in demonstrating that it is identical to an 
already approved product. Th   us, the abbreviated approval 
pathway speciﬁ  ed in Section 505(j) of the FD&C Act is 
not usually available for protein products.
An abbreviated pathway for the approval of biosimilars 
in the European Union has been proposed by the 
Committee for Medicinal Products for Human Use of the 
European Medicines Agency (EMA). In 2005, guidance 
was issued outlining the data necessary ‘to substantiate 
the claim of similarity used as the basis for a marketing 
authorization application (MAA)’ for large biopharma-
ceuticals [19]. Shortly thereafter, the EMA published a 
guideline that proposed the assessment expected before 
consideration of an MAA for ‘similar biological medicinal 
products containing biotechnology-derived proteins as 
active substance’ [20]. Both preclinical in vitro assays and 
in vivo animal studies and clinical studies in patients are 
required to compare the biosimilar with the reference 
product. If available, single- and multiple-dose pharma-
co  kinetic studies and pharmacodynamic studies using 
biomarkers relevant to the clinical eﬃ   cacy of the drug are 
necessary ‘to demonstrate clinical comparability’ between 
the biosimilar and the reference product. In most cases, 
‘comparative clinical trials’ are also needed to demon-
strate clinical equivalence between the biosimilar and the 
already approved reference product and to assess 
potential immunogenicity with chronic dosing. Because 
subtle diﬀ  erences between the biosimilar and the refer-
ence product may result in an unanticipated loss of 
eﬃ     cacy or adverse reactions, careful post-approval 
pharma  co  vigilance monitoring is expected. Th  e Bio-
similar Medicinal Products Working Party of the EMA is 
in the process of revising these guidelines and preparing 
other guidelines regarding the assessment of individual 
biosimilar protein drugs [21].
In the US, an abbreviated approval pathway for large 
biopharmaceuticals was established by the recent 
ratiﬁ  cation of the Patient Protection and Aﬀ  ordable Care 
(PPAC) Act of 2010 (H.R. 3590). Th   is bill was passed by 
the US Senate on 24 December 2009 and by the US 
House of Representatives by a very narrow margin (219 
for and 212 against) on 21 March 2010. Th  e following 
day, President Barack Obama signed this Act into law as 
Public Law 111-148. Section 7002 of the Patient Protec-
tion and Aﬀ  ordable Care Act, which is referred to as the 
Biologics Price Competition and Innovation Act of 2009, 
amends Section 351 of the PHS Act to create an 
abbreviated Biologic License Application (BLA) for 
‘highly similar’ biological products; the abbreviated BLA 
permits a follow-on biological product to be evaluated 
against only a single reference biological product [22]. To 
be considered for an abbreviated BLA, the biosimilar 
must have the same presumed mechanism of action, 
route of administration, dosage form, and potency as the 
innovator product. It may only be reviewed and approved 
for indications for which the FDA already has approved 
the innovator product.
Data obtained from analytical and animal studies and 
from at least one clinical trial, which must be conducted 
in patients with a disease for which the innovator product 
is licensed, are to be used to demonstrate that a follow-on 
biological product is ‘highly similar’ to the reference 
product, ‘notwithstanding minor diﬀ  erences in clinically 
inactive components’. Th  e clinical study must demon-
strate ‘safety, purity, and potency’ of the follow-on bio-
logical product, evaluate its pharmacokinetics and 
pharma  co  dynamics, and include an assessment to 
establish that it is not more immunogenic than the 
innovator reference product [22]. Once these studies 
have been completed, the HHS secretary must license an 
abbreviated BLA if she determines that the information 
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biological is ‘biosimilar’ to or ‘interchangeable’ with the 
innovator product [22]. Prior to licensing, the applicant 
must also consent to inspection of the manufacturing 
facility to ensure that it follows ‘good manufacturing 
practice’. However, at her ‘discretion’, the HHS secretary 
may ‘waive any of these requirements on a case-by-case 
basis’. Regardless, the same risk evaluation and mitigation 
strategies (REMSs) required of the innovator biologic 
agent licensed under the PHS Act are applied to the 
biosimilar [22].
Th  e FDA has established the Biosimilar Implemen-
tation Committee – co-chaired by Janet Woodcock, 
director of the Center for Drug Research and Evaluation, 
and Karen Midthun, acting director of the Center for 
Biologics Evaluation and Research –  to determine the 
process by which the FDA will approach the evaluation, 
review, and approval of abbreviated BLAs, as mandated 
by the Biologics Price Competition and Innovation Act 
[23]. It remains to be speciﬁ  ed whether the clinical trials 
required for an abbreviated BLA may demonstrate non-
inferiority of the biosimilar to the reference product or 
must prove superiority of the biosimilar to placebo or to 
another active comparator. Acceptable measures of 
eﬃ   cacy and the suitability of biomarkers as surrogates for 
clinical endpoints also remain to be clariﬁ  ed.
A follow-on biological product is deﬁ   ned as being 
‘interchangeable’ with the innovator product if it is 
‘biosimilar’ to that product and can be ‘expected to 
produce the same clinical result’ as that product in ‘any 
given patient’ and if there is no greater risk of safety or 
diminished eﬃ     cacy when alternating or switching 
between the follow-on biological and innovator products 
than when using the innovator product with no switch. If 
these conditions for interchangeability are met, the HHS 
secretary is required to determine that the biosimilar is 
‘interchangeable’ with the reference product at the time 
of approval [22]. If so, that biosimilar may be substituted 
for the prescribed innovator product by someone other 
than the health-care provider who issued the original 
prescription. In such a situation, a pharmacist would be 
allowed to substitute the ‘interchangeable’ biosimilar for 
a prescribed targeted biological therapy without 
involving the patient’s rheumatologist. However, unlike 
small-molecule drugs, a biopharmaceutical that is 
repeatedly interchanged with a similar biological agent 
may exhibit immunogenicity that could compromise the 
eﬃ     cacy and safety of both medications. Th  e clinical 
consequences of neutralizing antibodies developing to a 
non-redundant protein with an important biological 
function, such as erythropoietin, may be severe [15]. 
Th   us, it is extremely important that there not be frequent 
switching between the original protein product and the 
biosimilar, because even subtle diﬀ   erences, such as 
impurities introduced during manufacturing, may trigger 
an immune response to the biosimilar.
Th  e Biologics Price Competition and Innovation Act 
provides the manufacturer of the innovator product with 
economic protection by granting a period of ‘exclusivity’ 
during which follow-on products may not be approved 
[22]. A BLA for approval of a follow-on biological 
product may not be submitted for 4 years after the 
reference product was initially approved. Th  e FDA may 
not approve a BLA for a follow-on biological product 
until 12 years after the reference product was ﬁ  rst 
licensed. No additional period of exclusivity will be 
granted to a previously licensed biologic product when 
subsequent applications are made for a new indication, 
route of administration, dosage form, or dosing strength. 
However, each of the periods of exclusivity may be 
extended by 6 months if studies of the innovator 
biological product in the pediatric population are 
requested by the HHS secretary and carried out.
To encourage the development of biosimilars, the 
Biologics Price Competition and Innovation Act grants 
1 year of exclusive marketing rights to the ﬁ  rst follow-on 
biological that is approved as being ‘interchangeable’ with 
a reference product [22]. If patent litigation between the 
manufacturers of the follow-on and innovator products is 
ongoing, this period of exclusivity may be extended for 
up to 42 months.
Th   e recently enacted Biologics Price Competition and 
Innovation Act establishes an abbreviated pathway 
whereby biosimilars can be evaluated and approved in an 
accelerated manner. However, the details of the process 
by which the FDA will implement this pathway have yet 
to be worked out. As several biosimilar versions of 
targeted biological therapies for treatment of rheumatoid 
arthritis are being developed in Asia and Europe, the 
abbreviated BLA established by this Act sets up a 
regulatory mechanism for their approval in the US.
Th  e Biologics Price Competition and Innovation Act 
mandates that, to be approved, biosimilars be as safe and 
eﬀ   ective as the originally licensed biopharmaceutical. 
Although it would be ideal to reduce the cost of develop-
ment of biosimilars by abbreviating the BLA pathway and 
to pass that cost savings on to the patient, it is yet to be 
shown that fewer clinical trials than were required of the 
innovator biopharmaceutical will provide adequate data 
regarding the safety and eﬃ   cacy of a biosimilar. Meeting 
conditions of ‘interchangeability’ will ensure that the 
patient should not be adversely aﬀ  ected if a pharmacist 
substitutes a biosimilar for a prescribed biopharma-
ceutical. However, it is not readily apparent that many 
biosimilars will be determined to be ‘interchangeable’ 
with the reference product. Only time and experience 
will validate the adequacy of this new regulatory pathway 
for approval of biosimilars in the US.
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